Risk of Endocrine Adverse Events Higher With Combination Immunotherapy Regimens – AJMC.com Managed Markets Network
|
Risk of Endocrine Adverse Events Higher With Combination Immunotherapy Regimens
AJMC.com Managed Markets Network According to the recent study, published in JAMA Oncology, the use of immunotherapy regimens in oncology is expected to grow as the FDA approves more agents and further trials yield additional evidence supporting their use. However, patients receiving … |
